Regen BioPharma Inc logo

Regen BioPharma Inc

$ 0.01 +0.00015 (+2.4%) 03:19 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 33.60M
Enterprise V:
$ 33.10M
Volume:
9.91M
Avg Vol (2M):
33.07M
Volume:
9.91M
Market Cap $:
33.60M
PE Ratio:
At Loss
Avg Vol (2-Month):
33.07M
Enterprise Value $:
33.10M
PB Ratio:
0
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.07
Equity-to-Asset -12.1
Debt-to-Equity -0.19
Debt-to-EBITDA 1.1
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -47.74
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 18.73
9-Day RSI 29.73
14-Day RSI 36.79
6-1 Month Momentum % 38.1
12-1 Month Momentum % -72.56

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.05
Quick Ratio 0.05
Cash Ratio 0.01
Days Sales Outstanding 393.23

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -189

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -155.93
Net Margin % -2179.66
ROA % -547
ROIC % -1.61
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT 23.41
EV-to-EBITDA 23.41
EV-to-Revenue 142.22
Earnings Yield (Greenblatt) % 4.24

Financials

RGBP's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:RGBP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.236
EPS (TTM) ($) -0.001
Beta 4.38
Volatility % 89.78
14-Day RSI 36.79
14-Day ATR ($) 0.000906
20-Day SMA ($) 0.007145
12-1 Month Momentum % -72.56
52-Week Range ($) 0.00344 - 0.03567
Shares Outstanding (Mil) 4,970

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Regen BioPharma Inc Filings

Document Form Filing Date
No Filing Data

Regen BioPharma Inc Analysis

Share your research

Headlines

See More
No news.